Immix Biopharma (NASDAQ:IMMX) Upgraded to Hold at Wall Street Zen

Immix Biopharma (NASDAQ:IMMX - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a research note issued to investors on Friday.

Separately, HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Immix Biopharma in a research report on Wednesday, June 4th.

Immix Biopharma Trading Down 3.1%

Shares of NASDAQ:IMMX traded down $0.07 during mid-day trading on Friday, reaching $2.17. The stock had a trading volume of 170,910 shares, compared to its average volume of 154,025. The business's 50 day moving average price is $2.14 and its 200 day moving average price is $1.97. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $3.00. The company has a market cap of $60.50 million, a P/E ratio of -3.10 and a beta of 0.31.

Institutional Trading of Immix Biopharma

A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. acquired a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned about 0.06% of Immix Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.26% of the company's stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.